Please login to the form below

Not currently logged in
Email:
Password:

health technology assessment

This page shows the latest health technology assessment news and features for those working in and with pharma, biotech and healthcare.

NICE International relaunches, will offer advisory services

NICE International relaunches, will offer advisory services

This support will help those outside the UK develop similar systems which improve health and social care evidence-based decision making, and help to embed health technology assessment by allocating resources ... NICE has become one of the world’s most

Latest news

  • NICE’s long-serving chief exec Sir Andrew Dillon to step down NICE’s long-serving chief exec Sir Andrew Dillon to step down

    NICE quickly became the world’s  best-known and most prominent health technology assessment (HTA) body, and has set the standard for many other national institutes set up since then. ... NICE has made a significant contribution to improving outcomes

  • Who's calling the shots in European healthcare? Who's calling the shots in European healthcare?

    2019 has already been very eventful in terms of the debate about pharma’s future, including the question of how to proceed with plans for harmonisation of health technology assessment (HTA) ... The EMA is there to protect and promote public health, not

  • Europe urged to adapt faster to gene therapy challenges Europe urged to adapt faster to gene therapy challenges

    Resistance to high prices, even with novel payment models. Europe’s leading nations should commit to a rapid overhaul of health technology assessment (HTA) and bold initiatives such as new ... Better-adapted health technology assessment (HTA) methods,

  • European elections: Eurosceptics and Greens rise, but big parties hold on European elections: Eurosceptics and Greens rise, but big parties hold on

    An even clearer threat to public health and to pharma has been the anti-vax movement, which has gained a voice among Italy’s populist eruptions in particular. ... Probably the biggest outstanding issue is the future of plans to introduce EU-wide health

  • Akcea steals march on Alnylam with NICE approval Akcea steals march on Alnylam with NICE approval

    We hope that other health technology assessment and reimbursement agencies across Europe will take NICE’s lead in making inotersen available as a treatment option for patients with this disease.".

More from news
Approximately 2 fully matching, plus 153 partially matching documents found.

Latest Intelligence

  • Integrating patient reported outcomes into clinical trials Integrating patient reported outcomes into clinical trials

    Stung by products that failed to make a meaningful difference to people’s lives, payers and providers want to see evidence that therapies address the health problems patients face on a ... That disconnect is evident in drug reviews published by health

  • Leading AstraZeneca’s return to growth in Europe Leading AstraZeneca’s return to growth in Europe

    This should be top of the agenda, including proposals to streamline health technology assessment (HTA) across the EU,” said Reic. ... The proposals centre on creating a centralised procedure for the clinical assessment of new medicines, which would

  • Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe

    Alnylam's Theresa Heggie. Alnylam and its extraordinary ‘gene silencing’ technology is making its debut in Europe with the launch of Onpattro. ... treatment. Despite this progressive approach to pricing, the company has already been criticised by

  • The European Medicines Agency: PRIME’d for access? The European Medicines Agency: PRIME’d for access?

    EMA points out that there are three treatments in the PRIME scheme that were undergoing marketing authorisation assessment at the two-year point. ... It’s too soon to know if those treatments getting the PRIME treatment will go on to be given approval

  • Bluebird Bio: on the cusp of a gene therapy revolution Bluebird Bio: on the cusp of a gene therapy revolution

    In particular, it has looked to help small- to medium-sized companies and, eye-catchingly, also involves early dialogue with Europe’s payers and health technology assessment bodies. ... The important thing is that management doesn’t ignore the

More from intelligence
Approximately 0 fully matching, plus 46 partially matching documents found.

Latest appointments

  • VCLS appoints Carole Jones to senior market access role VCLS appoints Carole Jones to senior market access role

    her focus on expanding the company’s market access capabilities, spanning payer strategy, health economics and outcomes research (HEOR), health technology assessment (HTA) and communications support. ... The combination of world class regulatory and

  • EFPIA's Richard Torbett to move to the ABPI EFPIA's Richard Torbett to move to the ABPI

    with the Department of Health around the PPRS.”. ... At the ABPI Torbett will focus on pricing, the Pharmaceutical Price Regulation Scheme (PPRS), health technology assessments (HTA) and value assessment, as well as market access in the UK.

  • ABPI appoints value and access manager ABPI appoints value and access manager

    Rowland will work on a range of projects to improve patient access to innovative medicines, in line with the ABPI's strategic objectives around health technology assessment and market access. ... I am delighted to join the ABPI at this time of great

  • Former NICE chair joins board of biotech Former NICE chair joins board of biotech

    I no longer have anything to do with [NICE],” he told the FT, clarifying his future influence on the health technology assessment (HTA) body. ... His expertise in the cost-effectiveness of new pharmaceuticals and other issues in health economics will

  • Access Partnership expands its senior team Access Partnership expands its senior team

    His international experience extends to product development and commercialisation, health economics, health outcomes research, health technology assessment, market access and pricing strategies.

More from appointments
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 3 fully matching, plus 9 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hamell

Hamell is a full-service agency with a clear focus on delivering evidence-based, sustained behaviour change. So, whether you are looking...

Latest intelligence

Using human insights to push healthcare communications forward
This blog highlights the value of human perspectives, showing how insights can propel healthcare communications forward to ultimately improve lives...
RWE Blog 4: The place of real-world evidence in the market access strategy
The fourth and final blog in our latest series focuses on market access strategy. This follows our evaluation of the role of real-world data (RWD) and real-world evidence (RWE) in...
RWE Blog 3: Is real-world evidence the holy grail
We began our four-blog series by evaluating the role of real-world data (RWD) and real-world-evidence (RWE) in Real-world challenges and real-world data, and understanding the payer's perspective, in Payers use...

Infographics